Prescription Required
BIOMAB EGFR 50 MG INJECTION 10 ML is a targeted therapy used for treating head and neck cancers. It contains Nimotuzumab, a monoclonal antibody that blocks the Epidermal Growth Factor Receptor (EGFR), slowing down cancer cell growth. This prescription medication is administered under medical supervision and is often used alongside chemotherapy or radiation therapy.
Use with caution; liver function tests may be required.
Limited information on use in kidney disease; Inform your doctor if you have kidney disease.
Avoid alcohol during treatment.
May cause dizziness or fatigue; avoid driving if affected.
May be unsafe during pregnancy; consult your doctor to weigh benefits and risks.
Not recommended; consult a doctor.
Nimotuzumab works by binding to the EGFR protein present on cancer cells. By blocking EGFR, it prevents the growth and spread of cancerous cells. This targeted approach helps minimize damage to healthy cells, making it an effective and well-tolerated option for cancer treatment.
EGFR-positive cancer refers to tumors that overexpress the epidermal growth factor receptor (EGFR), leading to uncontrolled cell growth. This is common in head and neck cancers, as well as certain lung cancers. Targeted therapies like BIOMAB EGFR help block this receptor, slowing disease progression.
Active Ingredient: Nimotuzumab (50mg)
Uses : Treatment of EGFR-positive cancers
Dosage Form: Injection
Administration: Intravenous (IV)
Common Side Effects: Fatigue, rash, nausea, diarrhea
Alcohol Interaction: Avoid alcohol
BIOMAB EGFR 50 MG INJECTION is a targeted therapy for EGFR-positive cancers, particularly head and neck cancers. It works by blocking EGFR, slowing cancer growth. It is administered intravenously under medical supervision and is well-tolerated compared to conventional chemotherapy.
Content Updated on
Wednesday, 5 Feburary, 2025Prescription Required
Simplify your healthcare journey with Indian Government's ABHA card. Get your card today!
Create ABHA